Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04669587
Other study ID # ENZENO-C-101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 26, 2021
Est. completion date January 31, 2024

Study information

Verified date March 2022
Source EnhancedBio Inc.
Contact EnhancedBio Inc.
Phone 1-504-236-5452
Email sophia@enhancedbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For patients with ER-positive, HER2-negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. These patients showed good response to endocrine therapy. Fulvestrant, the approved SERD as monotherapy or in combination with CDK4/6 inhibitors, showed superior clinical benefit compared to other endocrine therapies. Fulvestrant exhibits differential mechanism of action from other endocrine therapy, such as tamoxifen, aromatase inhibitors, which indicates that direct blockage of ER might derive better clinical activity. However, due to its route of administration by intramuscular injection, the clinical application is limited, especially with long term use. In addition, a higher dose of fulvestrant at 500 mg showed better overall survival than the lower dose at 250 mg, suggesting that more profound ER pathway modulation could derive better clinical benefit. Therefore, a SERD with improved oral bioavailability and good safety profile which enables its overdose is anticipated to achieve a more satisfactory clinical outcome with better compliance of clinical use. Preclinical data indicates that ZB716 is a novel orally bioavailable, selective ERα degrader with full ER antagonism that demonstrates superior properties than Fulvestrant. Thus, it has a potential to be effective therapy for patients with ER-positive breast cancer. This is the first time ZB716 will be administered to humans. The principal aim of this study is to obtain safety and tolerability data when ZB716 is administered orally as monotherapy and in combination with palbociclib to subjects with ER-positive, HER2 negative advanced breast cancer. This information, together with the PK data, will help establish the doses and dosing regimen suitable for future studies in patients. The PD effect of ZB716 on the select biomarkers for cytochrome P450 (CYP)3A4 induction (4β hydroxycholesterol) and expression of ER, PgR, and Ki67 will also be investigated. The effect of ZB716 on antitumor activity as measured by objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), and PFS rate will also be investigated. The study will also investigate the effects of food on the PK of ZB716 monotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 106
Est. completion date January 31, 2024
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility [Inclusion Criteria] Subjects must satisfy all of the following criteria for study entry: 1. Subjects must be able to understand the nature of the trial and provide a signed and dated, written informed consent form (ICF) prior to any study-specific procedures, sampling, and analyses. 2. Subjects aged =18 years old at time of signing ICF (or country's legal age of majority if the legal age is >18 years). 3. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast. 4. Subjects with evidence of either locally advanced disease not amenable to radiation therapy or surgery in a curative intent, or metastatic disease. 5. ER-positive tumor (=1% positive stained cells) based on most recent tumor cell staining by immunohistochemistry (IHC) assay consistent with local standards. Note: If primary tumor is ER-positive and any further metastatic lesions are ER negative, the subject cannot be selected for inclusion. [Exclusion Criteria] Subjects who meet any of the following criteria will be excluded from study entry: 1. Treatment with any systemic anticancer therapies for locally advanced or metastatic breast cancer within 4 weeks or 5 half-lives of prior anticancer therapy, whichever is shorter, prior to initiation of study treatment. 2. Concurrent treatment with warfarin or phenytoin. 3. Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for all intraepithelial neoplasia, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer. 4. Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, major upper gastrointestinal (GI) surgery including gastric resection, or any other condition that may affect absorption of oral study drug. 5. Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis (eg, hepatitis B or hepatitis C virus), current alcohol abuse, or cirrhosis. Active viral or positive test for viral hepatitis as defined below: Note: If reports of serology test for HBV and HCV containing normal ranges issued by formal medical institutions within 28 days prior to C1D1 (and prior to informed consent) are available, these tests are exempt while screening. Unless required by local regulations, patients are not required to have HIV assessments at screening. Active infection is defined as requiring treatment with antiviral therapy or presence of positive test results for hepatitis B (hepatitis B surface antigen [HBsAg] and/or total hepatitis B core antibody [HBcAb]) or HCV antibody. Patients who test positive for HBcAb are eligible only if test results are also positive for hepatitis B surface antibody and polymerase chain reaction is negative for HBV DNA. Patients who are positive for HCV serology are only eligible if testing for HCV RNA is negative.

Study Design


Intervention

Drug:
ZB716
Pharmaceutical form: capsule Route of administration: oral
Palbociclib
Pharmaceutical form: capsule Route of administration: oral

Locations

Country Name City State
Korea, Republic of National Cancer Center Goyang-si Gyeonggi-do
Korea, Republic of CHA Bundang Medical Center, CHA University Seongnam-si
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Kangbuk Samsung Hospital Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital Seoul
United States Swedish Cancer Institute Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
EnhancedBio USA Inc. Zenopharm

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part A: To determine the RD(Recommended Dose) of ZB716 Incidence of study treatment-related DLTs at Cycle 1 At the end of Cycle 1 (each cycle is 28 days)
Primary Part B: To assess antitumor activities at the ZB716 RD in monotherapy Proportion of patients with CR(Complete Response), PR(Partial Response) or SD(Stable Disease) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by independent central reviewer relative to the total number of treated patients Baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered patient
Primary Part C: To determine the RD of ZB716 in combination with palbociclib Incidence of study treatment-related DLTs at Cycle 1 At the end of Cycle 1 (each cycle is 28 days)
Primary Part D: To assess antitumor activities in the combination therapy of ZB716 and Palbociclib Proportion of patients with CR(Complete Response), PR(Partial Response) or SD(Stable Disease) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by independent central reviewer relative to the total number of treated patients Baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered patient
Secondary Adverse Events (Part A, B, C and D) Number of patients with adverse events according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 5.0 grade scaling. Incidence of adverse events, including laboratory test results and electrocardiogram (ECG) findings that were adverse events Up to 30 days after last dose of ZB716 or ZB716 with Palbociclib
Secondary ORR(Object Response Rate) (Part A, B, C and D) Proportion of patients with CR(Complete Response) or PR(Partial Response) according to RECIST 1.1 assessed by investigator/local radiologist Baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered patient
Secondary CBR(Clinical Benefit Rate) (Part A and C) Proportion of patients with CR(Complete Response) or PR(Partial Response) or SD(Stable Disease) =16 weeks according to RECIST v.1.1 relative to the total number of treated patients by investigators/local radiologists Baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered patient
Secondary Duration of response (Part A, B, C and D) Time from initial response to the first documented tumor progression Baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered patient
Secondary Cmax of ZB716 after single dose (Part A, B, C and D) Cmax is maximum concentration observed. Cycle 0, Day -7 (Part A), Cycle 1, Day 1 (Part B, C and D) (each cycle is 28 days)
Secondary Tmax of ZB716 after single dose (Part A, B, C and D) Tmax is time to reach Cmax. Cycle 0, Day -7 (Part A), Cycle 1, Day 1 (Part B, C and D) (each cycle is 28 days)
Secondary AUC0-24 of ZB716 after single dose (Part A, B, C and D) AUC0-24 is area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (24 hours) Cycle 0, Day -7 (Part A), Cycle 1, Day 1 (Part B, C and D) (each cycle is 28 days)
Secondary Cmax of ZB716 after repeated dose (Part A, B, C and D) Cmax is maximum concentration observed. Cycle 2, Day 1 (Part A), Cycle 1, Day 15 (Part B, C and D) (each cycle is 28 days)
Secondary Tmax of ZB716 after repeated dose (Part A, B, C and D) Tmax is time to reach Cmax. Cycle 2, Day 1 (Part A), Cycle 1, Day 15 (Part B, C and D) (each cycle is 28 days)
Secondary AUC0-24 of ZB716 after repeated dose (Part A, B, C and D) AUC0-24 is area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (24 hours) Cycle 2, Day 1 (Part A), Cycle 1, Day 15 (Part B, C and D) (each cycle is 28 days)
Secondary Cmax of Palbociclib after single dose (Part C and D) Cmax is maximum concentration observed. Cycle 1, Day 1 (Part C and D) (each cycle is 28 days)
Secondary Tmax of Palbociclib after single dose (Part C and D) Tmax is time to reach Cmax. Cycle 1, Day 1 (Part C and D) (each cycle is 28 days)
Secondary AUC0-24 of Palbociclib after single dose (Part C and D) AUC0-24 is area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (24 hours) Cycle 1, Day 1 (Part C and D) (each cycle is 28 days)
Secondary Cmax of Palbociclib after repeated dose (Part C and D) Cmax is maximum concentration observed. Cycle 1, Day 15 (Part C and D) (each cycle is 28 days)
Secondary Tmax of Palbociclib after repeated dose (Part C and D) Tmax is time to reach Cmax. Cycle 1, Day 15 (Part C and D) (each cycle is 28 days)
Secondary AUC0-24 of Palbociclib after repeated dose (Part C and D) AUC0-24 is area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (24 hours) Cycle 1, Day 15 (Part C and D) (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2